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We have recently described a new class of dendrimers with tryptophan (Trp) on the surface that show
dual antiviral activities against HIV and EV71 enterovirus. The prototype compound of this family is a
pentaerythritol derivative with 12 Trps on the periphery. Here we complete the structure-activity
relationship studies of this family to identify key features that might be signiﬁcant for the antiviral ac-
tivity. With this aim, novel dendrimers containing different amino acids (aromatic and non-aromatic),
tryptamine (a “decarboxylated” analogue of Trp) and N-methyl Trp on the periphery have been pre-
pared. Dendrimer with N-Methyl Trp was the most active against HIV-1 and HIV-2 while dendrimer with
tyrosine was endowed with the most potent antiviral activity against EV71. This tyrosine dendrimer
proved to inhibit a large panel of EV71 clinical isolates (belonging to different clusters) in the low
nanomolar/high picomolar range. In addition, a new synthetic procedure (convergent approach) has
been developed for the synthesis of the prototype and some other dendrimers. This convergent approach
proved more efﬁcient (higher yields, easier puriﬁcation) than the divergent approach previously
reported.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Human immunodeﬁciency virus type 1 (HIV-1), the etiologic
agent of Acquired Immunodeﬁciency Syndrome (AIDS), is an
enveloped retrovirus with glycoproteins gp120 and gp41 on its
surface (Dumas et al., 2014; Terwilliger et al., 1990) while entero-
virus A71 (EV71), the etiologic agent of hand-, foot- and mouth-
disease (HFMD), is a (þ) RNA virus (genus Enterovirus, family
Picornaviridae) without envelope (Ng et al., 2015; Pourianfar and
Grollo, 2015)..
(UPV-CSIC), Valencia, Spain.
ecnología, Optica y Nutricion.
B.V. This is an open access article uAt present, more than 30 approved drugs or regimens exist for
the treatment of AIDS. These compounds, which are administrated
in the so-called Highly Active Anti-Retroviral Therapy (HAART)
(Butera, 2005; De Clercq, 2009; Pomerantz and Horn, 2003;
Volberding and Deeks, 2010), are primarily focused on the viral
enzymes integrase, reverse transcriptase and protease. HAART
keeps the disease under control, however is often associated with
the emergence of cross-resistant HIV strains and side-effects (Dube
and Sattler, 2010; Gaardbo et al., 2012; Hawkins, 2010; Margolis
et al., 2014; Rojas and Holguín, 2014). These limitations highlight
the need for new lead compounds and/or novel therapeutic ap-
proaches to ﬁght against HIV transmission and infection (Barre-
Sinoussi et al., 2013; Flexner, 2007; Kumari and Singh, 2013;
Tintori et al., 2014). In this respect, the entry of HIV into its target
cells represents an attractive target for the development of anti-
AIDS therapy (Este, 2003; Haqqani and Tilton, 2013; Hertje et al.,nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2010; Wilen et al., 2012). In fact, drugs that interfere with this early
event may represent an advantage over other existing therapeutic
approaches that target the viral enzymes such as reverse tran-
scriptase or protease, as theymay show remarkable efﬁcacy against
viruses resistant to these anti-HIV inhibitors and prevent the up-
take of the virus by uninfected CD4-positive cells. To date, only two
drugs among this category have been approved by the FDA, enfu-
virtide (T20) (Fletcher, 2003; Williams, 2003), a 36-amino acid
peptide that binds viral glycoprotein gp41, and maraviroc (Gulick
et al., 2008), a small-molecule CCR5-antagonist.
On the other hand, the therapeutic or prophylactic panorama for
EV71 infection is more limited as no approved drugs are available
for EV71 treatment to date. As already mentioned, this virus is the
etiologic agent of hand-, foot- and mouth-disease (HFMD), a mild
syndrome that affects mostly children below 6 years old (Chan
et al., 2011). Unlike other HFMD-related enteroviruses, EV71 also
may cause severe neurological problems like aseptic meningitis
and brainstem encephalitis, which may lead to cardiopulmonary
failure and death (Alexander et al., 1994; LuanYin et al., 1999;
McMinn, 2002). Patients with neurological syndromes often have
permanent neurological sequelae, with delayed neuro-
development, reduced cognitive function and polio-like paralysis.
Large EV71 outbreaks have been reported throughout theworld but
have been especially severe in the Paciﬁc region of Asia (Chang
et al., 2007; Chen et al., 2001). A very recent outbreak in Cata-
lonia, Spain, with 73 cases of enterovirus infection with neurolog-
ical complications suggests that the epidemiological pattern of
EV71 is going through a change also in Europe (ProMED, 2016;
ECDC, 2016). Therefore, effective antivirals are urgently needed
for prophylaxis or treatment of patients with severe EV71
infections.
We have recently reported that a new family of dendrimers
containing different central scaffolds and multiple (9e18) trypto-
phans (Trp) on the periphery, whose prototype is the pentaery-
thritol derivative 1 (Fig. 1), inhibit HIV infection (Rivero-Buceta
et al., 2015) and also proved to be potent, speciﬁc and selective
inhibitors of EV71 (Rivero-Buceta et al., 2016). These compounds
may inhibit an early step of the replicative cycles of both HIV and
EV71, presumably virus entry into its respective target cells. In the
case of HIV, the inhibition is probably due to the interaction with
the glycoproteins gp120 and gp41 of the viral surface while for
EV71, the mechanism of action is still under investigation (Rivero-Fig. 1. Structure of the prototype pentaerythritol derivative 1.Buceta et al., 2015, 2016).
Preliminary structure-activity relationship studies for EV71 and
HIV on this family of dendrimers are very similar and revealed that
the absence of Trps on the periphery is detrimental for antiviral
activity and that a multivalent presentation of Trp is important for
both activities, being 9e12 Trps sufﬁcient for activity.
Here we decided to extend the structure-activity relationship
studies of this class of compounds. In particular, three aspects have
now been studied. The ﬁrst one is the nature of the amino acid
residues on the periphery. This was assessed by replacing the Trp
residue of the prototype by aromatic (phenylalanine and tyrosine)
and non-aromatic (alanine) amino acids. The second one is the
importance of the carboxylic acid on the periphery. This was
elucidated by preparing the corresponding tryptamine derivative, a
“decarboxylated” analogue of the prototype. The third one is the
importance of the NH of the indol moiety on the activity. This was
explored by using a N-Me analogue of Trp.
Finally, we were also interested in the development of an opti-
mized synthetic procedure that would allow an efﬁcient multi-
gram synthesis of the prototype 1, needed for additional biolog-
ical studies or mass production. With this aim, an alternative syn-
thetic procedure, based on a convergent approach, has been
explored.
2. Materials and methods
2.1. Synthesis
Commercial reagents and solvents were used as received from
the suppliers without further puriﬁcation unless otherwise stated.
Dichloromethane was dried prior to use by distillation from CaH2
and stored over Linde type activated 4 Å molecular sieves.
Analytical thin-layer chromatography (TLC) was performed on
aluminum plates pre-coated with silica gel 60 (F254, 0.25 mm).
Products were visualized using an ultraviolet lamp (254 nm) or by
heating on a hot plate (approx. 200 C), directly or after treatment
with a 5% solution of phosphomolybdic acid or vanillin in ethanol.
For reversed phase puriﬁcation, a Biotage HPFC (High Perfor-
mance Flash Chromatography) puriﬁcation system using water/
acetonitrile (100:0 to 0:100) as eluent was used.
For HPLC analysis an Alliance 2695 (Waters) equipped with a
PDA (Photo Diode Array) detector Waters 2996 was used. Aceto-
nitrile was used as mobile phase A with 0.08% of formic acid, and
water was used as mobile phase B with 0.1% of formic acid at a ﬂow
rate of 1 mL min1. Two different methods were used, one on a
XBridge C18 (2.1  100 mm, 3.5 mm) column with 5e80% of A, that
will be noted as tR(X), and the other on a SunFire C18 (4.6  50 mm,
3.5 mm) column with 0e100% of A, that will be noted as tR(S). All
retention times are quoted in minutes.
Melting points were measured on a Mettler Toledo and are
uncorrected.
NMR spectra (1H, 13C NMR) were recorded on a 300MHz (Varian
Inova 300) and 500 MHz (Varian System 500) spectrometers, using
(CD3)2SO and CD3OD as solvents. Chemical shift (d) values are re-
ported in parts per million (ppm) relative to tetramethylsilane
(TMS) in 1H and CDCl3 (d ¼ 77.0) in 13C NMR. Coupling constant (J
values) are reported in hertz (Hz), and multiplicities of signals are
indicated by the following symbol: s (singlet), d (doublet), m
(multiplet), bs (broad singlet).
Mass spectra (MS) were registered in a quadrupole mass spec-
trometer 1100 Hewlett Packard equipped with an electrospray
source. HRMS was registered in an Agilent 1200 Series LC system
(equipped with a binary pump, an autosampler, and a column
oven) coupled to a 6520 quadrupole-time of ﬂight (QTOF) mass
spectrometer using an ESI interface working in the positive-ion and
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(Santa Clara, CA). The electrospray voltage was set at 4.5 kV, the
fragmentor voltage at 150 V and the drying gas temperature at
300 C. Nitrogen (99.5% purity) was used as nebulizer (207 kPa) and
drying gas (6 L min1), while nitrogen of higher purity (99.999%)
was used as the collision gas. Data acquisition and processing were
performed using Agilent Mass HunterWorkstation Acquisition Rev.
B.02.00 software.
Microanalyses were obtained with a Heraeus CHN-O-RAPID
instrument.
The purity of ﬁnal compounds was at least 95%. The purity has
been determined by high resolution mass spectrometry (HRMS,
“exact mass”) and reverse phase-HPLC.
Details regarding the synthesis and characterization of the
compounds can be found in the Supplementary material.
2.2. Biological methods
2.2.1. Anti-HIV activity assay
The compounds were evaluated for their inhibitory activity
against HIV-1 (NL4.3) and HIV-2 (ROD) infection in MT-4 cell cul-
tures. Brieﬂy, MT-4 cells (1  106 cells/mL) were pre-incubated for
30 min at 37 C with the test compounds in a 200 ml-96-well plate.
Next, NL4.3 virus was added at 100 CCID50 of the viral stock. The
cytopathic effect was scored microscopically 5 days post-infection,
and the 50% effective concentration (EC50) values were determined
using the MTS method.
2.2.2. Surface plasmon resonance experiments for evaluation of the
binding of the compounds to gp120 and gp41
Recombinant gp120 protein from the HIV-1 IIIB strain (Immu-
noDiagnostics Inc., Woburn, MA) (produced in cell cultures of chi-
nese hamster ovary cell cultures) and recombinant gp41 HIV-
1(HxB2) (Acris Antibodies GmbH, Herford, Germany) were cova-
lently immobilized on the carboxymethylated dextran matrix of a
CM5 sensor chip in 10 mM sodium acetate, pH 4.0, using standard
amine coupling chemistry up to a ﬁnal density of, respectively, 700
RUs and 580 RUs. All interaction studies were performed at 25 C on
a Biacore T200 instrument (GE Healthcare, Uppsala, Sweden). The
compounds 10 and 24 were diluted in HBS-P (10 mM HEPES,
150 mMNaCl and 0,05% surfactant P20; pH 7.4), and supplemented
with 5% dimethyl sulfoxide (DMSO, Merck) and 10 mM Ca2þ at a
concentration of 50 mM. Samples were injected for 2 min at a ﬂow
rate of 30 ml/min followed by a dissociation phase of 2 min. The
sensor chip surface was regenerated with an injection of 50 mM
NaOH. A reference ﬂow cell was used as a control for non-speciﬁc
binding and refractive index changes. Several buffer blanks were
used for double referencing. A DMSO concentration series was
included to eliminate the contribution of DMSO to the measured
response. The binding afﬁnity (KD) was calculated for 24 based on
the data obtained in the sensorgram.
2.2.3. Antiviral activity against EV71
EV71 BrCr laboratory adapted strain and clinical isolates repre-
sentative of B genogroup (B2 sub-genogroup: 11,316; B5 sub-
genogroup: TW/96016/08 and TW/70902/08) and C genogroup
(C2 sub-genogroup: H08300 461#812; C4 subgenogroup: TW/
1956/05 and TW/2429/04) were used at a low multiplicity of
infection (MOI) in a standardized antiviral assay. Brieﬂy, a serial
dilution of the compounds was prepared in assay medium that was
added to an empty microtiter 96 well-plate, after which the virus
inoculum was added ﬁrst, followed by a suspension of freshly
harvested rhabdosarcoma (RD) cells (2 10^4 cells/well). While the
cells were settling to the bottom, the virus was allowed to infect
them in the presence of compound. The assay plates wereincubated at 37 C, 5% CO2 with virus inoculum and compounds
until full virus einduced cell death was observed in the untreated,
infected controls (3e4 days post-infection). Subsequently, the
antiviral effect was quantiﬁed using a colorimetric readout with 3-
(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium/phenazine methosulfate (MTS/PMS
method) and the concentration of compound at which 50% inhi-
bition of virus-induced cell death would be observed (EC50) was
calculated from the antiviral dose-response curves. A similar assay
setupwas used to determine the adverse effect of the compound on
uninfected, treated cells for calculation of the CC50 (concentration
of compound that reduces overall cell health with 50% as deter-
mined by the MTS/PMS method). Selectivity index (SI) was calcu-
lated as the ratio of CC50 to EC50.
3. Results and discussion
3.1. Chemistry
Firstly, the novel amino acid dendrimers were obtained
following the divergent approach previously described for 1
(Rivero-Buceta et al., 2016). In this approach, dendrimers were built
starting from the central core and growing towards the periphery.
The commercially available pentaerythritol scaffold 2, that in-
corporates four aminotriester (Behera's amine) branched arms, has
been chosen as central core (Scheme 1). Deprotection of the t-butyl
protecting groups of 2, followed by condensation of the resulting
poly acid 3 with the corresponding (OMe or OBn) protected amino
acids gave intermediates 4 (25%), 6 (15%) and 8 (23%). Saponiﬁca-
tion (OMe esters) or hydrogenation (OBn esters) of the protecting
ester moieties of these intermediates afforded the ﬁnal compounds
5, 7 and 10, bearing twelve amino acids on the periphery, in
quantitative yields. This divergent approach represents a short
route in terms of synthetic steps. However, the high number of
covalent bonds that should be simultaneously formed in the ﬁnal
coupling step (12) leads to incomplete reactions and mixtures of
dendrimers with very similar chromatographic properties that
were very difﬁcult to purify. Particularly arduous was the synthesis
and puriﬁcation of the triptamine derivative 11 that was obtained
in a very low yield (5%). In addition, the N-Me analogue of Trp could
not be obtained by this method. An alternative convergent
approach was then explored. In this convergent approach, building
blocks, called dendrons, are constructed ﬁrst and then attached to
the central core in the ﬁnal step of the synthesis.
For the dendron construction, the commercially available ami-
notriester 12 (Behera's amine) was selected as the starting material
(Scheme 2). First, the amino group in 12 was protected with the
ﬂuorenylmethyl oxycarbonyl group (Fmoc) to afford intermediate
13 (Carpino and Han, 1972; Karasugi et al., 2012) (73%). Depro-
tection of the t-butyl protecting groups of 13 afforded dendron 14
(Carpino and Han, 1972; Karasugi et al., 2012) in quantitative yield.
Reaction of 14 with H-Trp-OMe$HCl in the presence of HATU as
coupling reagent and DIPEA as base gave intermediate 15 (95%)
whose subsequent Fmoc deprotection, using piperidine, afforded
dendron 18 (95%), with a reactive amino group as focal point. This
free amino group enables further attachment of 18, through the
formation of amide bonds, to the central pentaerythritol scaffold 21
(Flores et al., 2014; Newkome and Weis, 1996) to afford interme-
diate 22. Finally, methyl ester deprotection (LiOH/H2O) of 22
afforded compound 1 in quantitative yield. Compared to the
divergent approach, the convergent methodology considerably
improves the global yield of dendrimer 1 (20% versus 4%).
Next, and based on the good results of the convergent approach,
the same synthetic methodology was applied for the synthesis of
the tryptamine 11 and (NMe)Trp 24 dendrimers, for which the
Scheme 1. Synthesis of dendrimers 4e11 by the divergent approach.
B. Martínez-Gualda et al. / Antiviral Research 139 (2017) 32e40 35divergent approach gave poor results (in the case of 11) or even
failed (in the case of 24). In both cases the key dendron interme-
diate 14 was reacted with Trp (NMe)-OMe or triptamine to give
dendrons 16 (53%) and 17 (67%), respectively. Fmoc deprotection,
followed by coupling of the resulting intermediates 19 and 20 with
the pentaerytritol derivative 21 gave compounds 23 (27%) and 11
(16%). Methyl ester deprotection of 23, as described above (LiOH/
H2O) gave 24 in quantitative yield.
Thus, compared to the divergent approach, the convergent
methodology improved considerably the global yield of the trypt-
amine dendrimer 11 (16% versus 5%) and allowed the synthesis of
24 that could not be obtained by the divergent approach.
All the synthesized compounds were characterized by 1H and
13C NMR spectroscopies and HRMS.
3.2. Biological results
3.2.1. Anti-HIV activity of the test compounds
Dendrimers 5, 7, 10, 11 and 24 were ﬁrst evaluated for theirinhibitory effects against HIV-1 and HIV-2 replication in CD4 cell
culture. Table 1 summarizes the results of this evaluation. The
antiviral data of the prototype 1, with Trps on the periphery, is also
included as a reference, as well as dextran sulfate-5000 (DS-5000),
and pradimicin A. DS-5000 is a negatively charged HIV adsorption
inhibitor (Baba et al., 1988) and pradimicin A represents a gp120
carbohydrate-binding entry inhibitor (Balzarini et al., 2007). These
control compounds showed antiviral activities in the range as
previously reported (Baba et al., 1988; Balzarini et al., 2007).
Alanine (5) and phenylalanine (7) dendrimers, with methyl and
phenyl side chains, respectively, were inactive. However, tyrosine
derivative 10, with a phenolic OH side chain, showed signiﬁcant
anti-HIV activity. It was three-fold less active against HIV-1, and
equally active against HIV-2 than the prototype 1, with an indol side
chain. This result suggests that the nature of the side chain of the
amino acid is very important for the activity and in particular, the
indol moiety was preferred over the phenolic moiety. Tryptamine
derivative 11 was 19-fold less active than the prototype 1 against
HIV-1 showing the importance of the concomitant presence of the
Scheme 2. Synthesis of compounds 1, 11 and 24 by the divergent approach.
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Interestingly, the replacement of the indole moiety by an N-
methyl indole moiety improved the activity of compound 24 versusTable 1
Anti-HIV activity of the selected group of compounds.
Compound EC50a (mM) HIV-1 EC50a (m
5 >100 >100
7 >28 >28
10 6.4 ± 1.4 20 ± 15
11 45 77
24 1.7 ± 0.0 7.3 ± 2.
1 2.3 ± 0.3 22 ± 2.8
DS-5000 0.07 ± 0.02 0.03 ± 0
Pradimicin A 3.3 ± 1.2 5.9 ± 3.
Data are the mean ± S.D. of at least 2 to 3 independent experiments.
a 50% Effective concentration, or the concentration required to inhibit HIV-induced cy
b 50% Cytostatic concentration, or the compound concentration required to inhibit CD
c Molecular weight of the molecules expressed as g/mol.the prototype 1. This result suggests that the free indole-NH is not
crucial for activity. Dendrimer 24 was also active against HIV-2 at
subtoxic concentrations, but the inhibitory potential provedM) HIV-2 CC50b (mM) MWc (g/mol)
>100 2194.25
28 3287.58
>100 3299.40
>100 3047.72
8 >100 3744.15
>100 3575.84
.01 >20 ~5000
7 >100 842.80
topathicity by 50%.
4 T cell proliferation by 50%.
B. Martínez-Gualda et al. / Antiviral Research 139 (2017) 32e40 37inferior to HIV-1 inhibition, as also observed for dendrimer 10.
It should be emphasized that the activity showed by our com-
pounds (EC50 ¼ 1.7e6.4 mM), in the low micromolar range, is very
similar to that of pradimicin A (EC50 ¼ 3.3 mM), the gp120
carbohydrate-binding entry inhibitor (Balzarini et al., 2007) used as
control (Table 1). However, pradimicin A is a structurally complex
molecule difﬁcult to synthesize that has to be obtained by
fermentation. By contrast, our dendrimers are synthetic molecules
easy to prepare and suitable to modiﬁcation by conventional syn-
thetic procedures.
In addition, our compounds have a precise structure and a well-
deﬁned composition because they have been synthesized with
complete control over the size, shape and surface functionalization.
This is in clear contrast with those happen with other negatively
charged HIV entry inhibitors such as sulfated polysaccharides of
which dextran sulfate-5000, that has been used as control, is a
representative example (Baba et al., 1988). The antiviral activities of
these compounds vary depending on the size (molecular weight)
and density (charge distribution) of the anionic groups (-OSO3)
present on the molecules. For this reason, it is very difﬁcult to
obtain standardized preparations of dextran sulfates or other
sulfated polymers (De Clercq, 1995). In addition, in certain systems,
the sulfate groups (-OSO3) present in these compounds can be
subjected to hydrolysis (release) by sulfatases (Balzarini and Van
Damme, 2007) resulting in inactivation of the compounds.
For all of these reasons and based on the synthetic accessibility,
well deﬁned molecular structure, presence of COOH instead of
eOSO3 and relatively moderate Molecular Weight (3000 Da vs
5000 to 500,000 Da of dextran sulfates) the therapeutic possibil-
ities of our compounds might be broader than those of dextran
sulfate or pradimicin, that have been used as control compounds in
the present study.
3.2.2. SPR interaction experiments for 10 and 24 with HIV-1 gp120
and gp41
SPR experiments performed with the most active compounds,
10 and 24, revealed that they dose-dependently interact with the
glycoproteins gp120 and gp41 of the HIV envelope (Fig. 2). In this
respect, the 4-fold better anti-HIV-1 activity of compound 24
versus 10 correlated with the ~ 7-fold higher binding amplitude of
24 to HIV-1 gp120 and gp41 than 10.
The KD value (afﬁnity constant) of the most potent HIV-1 in-
hibitor 24 (EC50: 1.7 mM) was determined by SPR analysis and
compared with the KD value of the prototype compound 1 (EC50:
2.2 mM) that had earlier been determined (Rivero-Buceta, personal
communication). Whereas 1 had a KD of 6.7 mM for HIV-1 gp120
and 18 mM for HIV-1 gp41, 24 proved somewhat superior (KD:
1.53 mM for HIV-1 gp120 versus 3.40 mM for HIV-1 gp41) (Fig. 3).
Thus, both 1 and 24 were endowed with comparable anti-HIV-1
activity in cell culture, and with pronounced afﬁnities against gly-
cosylated HIV-1 gp120 and gp41 proteins. In this respect, they were
equally inhibitory against HIV-1 as the non-peptidic carbohydrate-
binding antibiotic pradimicin S, although pradimicin S has a ~ 5-
fold higher afﬁnity for HIV-1 gp120 than 24 (Balzarini et al.,
2010). It should be kept in mind that different afﬁnities of 1 and
24 for HIV-1 gp120 can be explained by differential interactions of
these compounds with the different glycan types that are present
on HIV-1 gp120.
3.2.3. Anti-EV71activity of the test compounds
The new synthesized compounds were also evaluated for their
inhibitory effects against EV71 in vitro. Tryptophan prototype 1was
included in the assay together with pirodavir, a potent EV71 capsid
binder, as reference compounds (Tijsma et al., 2014; Andries et al.,
1992).In particular, dendrimers 5, 7, 10, 11 and 24 were evaluated for
selective antiviral activity (EC50) against the BrCr laboratory-
adapted strain of EV71 in a cell-based assay on rhabdomyosar-
coma (RD) cells, which are known for their high susceptibility to
EV71-induced cell death (Yamayoshi et al., 2009). Cell viability
(CC50) was also assessed in a similar setup with compound-treated,
uninfected cells. Overall, with a range of activity 0.4e7.2 mM, the
dendrimers showed a better antiviral activity against EV71 BrCr
than HIV (range of activity: 1.7e45 mM) (Table 2).
Interestingly, the SAR for EV71 revealed a similar proﬁle to that
observed for HIV. The tyrosine derivative 10 and theN-Me indole 24
showed the best antiviral activity against EV71. However, com-
pound 24 was three-fold less active than the prototype whereas it
was as active as the prototype against HIV. The tryptamine deriv-
ative 11 proved inactive similarly to HIV, indicating the importance
of the negative (carboxyl) charges in the molecule as a concomitant
prerequisite for antiviral activity.
The most active compounds,10 and 24,were evaluated in virus-
cell-based assays against a panel of EV71 clinical isolates repre-
sentative for the different (sub)genogroups (A, B2, B5, C2 and C4)
(Table 3). Compound 1 was included as reference.
Similar to the results found for the Trp prototype 1 (EC50 values
ranging between 0.2 nM and 1.1 nM) (Rivero-Buceta el al., 2016),
the tyrosine analogue 10 inhibited the replication of all EV71
strains, with 50% effective concentrations (EC50s) in the low-
nanomolar/high-picomolar range (EC50s ranging between 0.7 nM
and 6.7 nM). A remarkably lower activity was observed for the N-
Me indole compound 24. Nonetheless, it achieved full inhibition of
all three genogroups with EC50 values ranging between 51 nM and
180 nM. This result clearly demonstrated that the presence of hy-
drophilic groups (NH, OH) on the aromatic ring of the side chain of
the amino acid is beneﬁcial for anti-EV71 activity.
Interestingly, as previously reported (Rivero-Buceta et al., 2016),
the selected dendrimer compounds were more potent inhibitor of
clinical EV71 isolates than the BrCr laboratory strain (Table 3). Such
a difference was not observed when cells were treated with Pir-
odavir (data not shown). This ﬁnding suggests that dendrimersmay
act with a different mechanism than Pirodavir to block EV71 entry
(Tijsma et al., 2014). Further investigations are currently ongoing to
determine the mode of action of dendrimers.
To determine at which stage of the virus replication cycle the
compounds act, a time-of-drug-addition study was performedwith
the most active, 10. In this experiment the capsid binder pirodavir
and the 3C protease inhibitor rupintrivir were used as reference
compounds (Fig. 4) (Thibaut et al., 2011; Tijsma et al., 2014). Similar
to the results found for pirodavir and the prototype 1 (Rivero-
Buceta el al., 2016), clear inhibition of virus replication was
observed only when the drug was added during or before infection.
Compound 10, like 1 and pirodavir, lost its activity when added
after the infection period. This correlates with the observation that
the compounds inhibit HIV entry. The viral 3C protease inhibitor,
rupintrivir, lost its activity when added 6 or 7 h after infection,
which is in line with its mechanism of action.
4. Conclusions
Starting from 1 as prototype, novel dendrimers containing
different aromatic and non-aromatic amino acids, tryptamine (a
“decarboxylated” analogue of Trp) and N-Methyl Trp on the pe-
riphery have been synthesized. A new synthetic procedure
(convergent approach) has been developed for the obtention of
these compounds and the prototype 1. This convergent approach
proved to bemore efﬁcient (higher yields, easier puriﬁcations) than
the divergent approach and was crucial for the synthesis of den-
drimers whose synthesis either proved inefﬁcient (triptamine) or
Fig. 2. SPR analysis of the interaction of 10 and 24 with HIV-1 gp120 and gp41.
Fig. 3. Apparent KD for 24-gp120 and 24-gp41.
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Table 2
Antiviral activity of dendrimers against the BrCr lab strain of EV71 in RD cells.
Compound EC50a (mM) EV71 EC90a (mM) EV71 CC50b (mM) SI
5 >46 >46 ND ND
7 7.2 ± 0.2 >10 >32 >4
10 0.4 ± 0.1 0.7 ± 0.4 >30 78
11 >33 >33 ND ND
24 3.6 ± 1.1 5.3 ± 0.9 >27 7.5
1 0.3 ± 0.1 0.5 ± 0.1 >100
Pirodavir 0.3 ± 0.1 0.6 ± 0.2 >54
ND ¼ Not Determined.
a All values are in micromolar (mM) and are a summary of multiple dose-response
curves (>2) in multiple independent (>1) experiments.
b CC50 ¼ concentration of compound at which a 50% reduction in cell viability is
observed; EC50¼ concentration of compound at which the virus-induced cytopathic
effect is reduced by 50%; SI ¼ selectivity index (CC50/EC50).
Table 3
Evaluation of the broad-spectrum antiviral effect of compounds 10 and 24 against a
representative panel of clinical EV71 isolates in RD cells.
EV71 Genogroup Virus strain EC50 (nM)a
1 10 24
A BrCr 285 ± 70 390 ± 140 3560 ± 1620
B2 11,316 0.4 ± 0.0 6.7 ± 3.2 160 ± 10
B5 TW/96016/08 0.2 ± 0.0 0.7 ± 0.1 51 ± 18
TW/70902/08 0.2 ± 0.1 1.0 ± 0.3 66 ± 11
C2 H08300 461#812 1.1 ± 0.3 2.0 ± 0.4 180 ± 10
C4 TW/1956/05 0.2 ± 0.2 0.3 ± 0.2 58 ± 6
TW/2429/04 0.3 ± 0.2 0.4 ± 0.1 59 ± 18
a All values are in nanomolar (nM) and are obtained in multiple (>2) independent
(>1) experiments. Following microscopic quality control, at least at one concen-
tration of compound, no virus-induced cell death was observed and the compound
did not cause an adverse effect on the host cell or monolayer morphology.
Fig. 4. Effects of pirodavir (capsid binder), rupintrivir (3C protease inhibitor), and
compound 10 in a time-of-drug-addition assay.
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Aromatic amino acids Trp (present on the prototype, 1) and Tyr
(present on 10), with their respective indol and phenol moieties
and free COOHs, are required for anti-HIV and anti-EV71 activity.
Tryptamine derivative 11 was 19-fold less active against HIV than
the prototype 1 and inactive against EV71, thus showing the
importance of the COOHs for activity. Dendrimer 24, with N-
Methyl Trp on the periphery, was slightlymore active against HIV-1
and HIV-2 than the prototype, which suggests that the NH of the
indole moiety is not crucial for HIV activity. However, dendrimer 24
was three-fold less active than the prototype against EV71, sug-
gesting that for the anti-enteroviral activity, this NH is important
since it may probably be involved in a hydrogen bond with its
corresponding binding site. Dendrimer 10, with tyrosine, was
endowed with the most potent antiviral activity against EV71. Thiscompound represents a novel low-nanomolar inhibitor of the
clinical isolates of enterovirus A71 while dendrimer 24, with N-
Methyl Trp, was the most active against HIV-1.
In conclusionwe report herein a family of dendrimers with dual
action against HIV and EV71 that deserve further studies and
development. The ability of these compounds to act early in the HIV
replicative cycle, before HIV enters the host cell, makes them ideal
candidates for use as microbicides, compounds in which exist a
great interest, especially in developing countries, where live more
than 90% of HIV-infected people, whose access to the conventional
anti-HIV therapies of the developed world are very limited (WHO,
2016; UNAIDS, 2016). On the other hand, and because this class of
molecules show extremely high potency against clinical isolates of
EV71, they may be of signiﬁcant interest for future therapeutic/
prophylactic strategies against this virus.
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